CN Patent

CN118908962A — 作为hpk1的降解剂的异双功能化合物

Assigned to Icahn School of Medicine at Mount Sinai · Expires 2024-11-08 · 2y expired

What this patent protects

本发明涉及作为HPK1的降解剂的异双功能化合物。公开了包含HPK1配体、降解/破坏标签和连接基团的造血祖细胞激酶1(HPK1)降解/破坏化合物和在HPK1介导的疾病的治疗中使用此类化合物的方法。

USPTO Abstract

本发明涉及作为HPK1的降解剂的异双功能化合物。公开了包含HPK1配体、降解/破坏标签和连接基团的造血祖细胞激酶1(HPK1)降解/破坏化合物和在HPK1介导的疾病的治疗中使用此类化合物的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN118908962A
Jurisdiction
CN
Classification
—
Expires
2024-11-08
Drug substance claim
No
Drug product claim
No
Assignee
Icahn School of Medicine at Mount Sinai
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.